Camlin Fine Sciences shareholders approve FY26 financials, reappoint directors

2 min read     Updated on 11 Aug 2026, 05:15 PM
scanx
Reviewed by
Shriram SScanX News Team
AI Summary

Camlin Fine Sciences Limited concluded its 33rd AGM on August 11, 2026, with shareholders approving FY26 financials and reappointing directors Harsha Raghavan and Jens Van Nieuwenborgh. Voting participation reached 56.83%, with all resolutions passing by over 99.99% majority. The Statutory Auditor issued an unqualified report, and the Cost Auditor’s remuneration for FY27 was ratified.

powered bylight_fuzz_icon
47994331

*this image is generated using AI for illustrative purposes only.

Camlin Fine Sciences Limited shareholders approved the company’s audited financial statements for the fiscal year ended March 31, 2026, and reappointed two non-executive directors at its 33rd Annual General Meeting (AGM) held on August 11, 2026. The meeting, chaired by Chairman and Managing Director Ashish Dandekar, was conducted through Video Conferencing (VC) / Other Audio Visual Means (OAVM) in compliance with Ministry of Corporate Affairs and Securities and Exchange Board of India (SEBI) circulars. All four resolutions placed before the shareholders were passed with requisite majority, reflecting strong support from both promoter and public stakeholders.

The AGM transacted ordinary business including the adoption of standalone and consolidated financial statements for FY26, alongside the re-appointment of Harsha Raghavan and Jens Van Nieuwenborgh as Non-Executive Non-Independent Directors, who retired by rotation. Under special business, shareholders ratified the remuneration of the Cost Auditor for the financial year ending March 31, 2027. The proceedings were scrutinized by Jayant Ranade of JHR & Associates, appointed as Scrutinizer pursuant to Section 108 of the Companies Act, 2013 and Regulation 44 of the SEBI Listing Regulations.

Voting participation was robust, with 56.83% of outstanding shares polled across all resolutions. Promoter and Promoter Group shareholders, holding 92,264,053 shares, voted in favor of all resolutions with 100% support. Public Institutional shareholders also demonstrated high engagement, polling over 84% of their holdings. Remote e-voting was open from August 8 to August 10, 2026, while additional voting occurred during the live meeting session.

Voting Results Summary

Resolution Total Votes Polled Votes In Favor % In Favor Votes Against % Against
Adoption of Financial Statements (FY26) 109,167,921 109,167,821 99.9999% 100 0.0001%
Re-appointment of Harsha Raghavan 109,219,228 109,217,553 99.9985% 1,675 0.0015%
Re-appointment of Jens Van Nieuwenborgh 109,219,128 109,217,453 99.9985% 1,675 0.0015%
Ratification of Cost Auditor Remuneration 109,219,276 109,219,126 99.9999% 150 0.0001%

The Statutory Auditor’s report contained no qualifications or adverse remarks, as noted by the Chairman during the proceedings. The Scrutinizer’s consolidated report confirmed that no invalid votes were identified during the scrutiny process. A limited number of abstentions were recorded for specific resolutions but were classified separately as votes not cast.

What the Numbers Show

The near-unanimous approval of all resolutions underscores stable shareholder confidence in Camlin Fine Sciences’ governance structure. The promoter group’s complete alignment with all proposals, combined with high institutional participation, suggests minimal dissent regarding the company’s strategic direction and financial reporting for FY26. The negligible percentage of votes against any resolution indicates broad consensus among equity holders.

Historical Stock Returns for Camlin Fine Sciences

1 Day5 Days1 Month6 Months1 Year5 Years
+0.91%-2.31%-2.36%-25.01%-44.52%-26.31%

How might the reappointment of Harsha Raghavan and Jens Van Nieuwenborgh influence Camlin Fine Sciences' strategic focus on specialty chemicals in the upcoming fiscal year?

Given the near-unanimous shareholder approval, what specific operational or financial targets has management set for FY27 to maintain this high level of investor confidence?

Could the robust institutional participation (84% polling) indicate a shift in sentiment regarding the company's valuation or growth prospects compared to previous years?

Camlin Fine Sciences Q1 Results: Earnings call scheduled for Aug 11, 2026

1 min read     Updated on 04 Aug 2026, 07:39 PM
scanx
Reviewed by
Suketu GScanX News Team
AI Summary

Camlin Fine Sciences Limited has announced a Q1 FY27 earnings conference call on August 11, 2026 at 5:00 PM IST to discuss unaudited financial results for the quarter ended June 30, 2026. The call will be led by Chairman & Managing Director Mr. Ashish Dandekar, Managing Director Mr. Nirmal Momaya, and CFO Mr. Santosh Parab. Dial-in access has been provided for participants across India, the USA, UK, Singapore, and Hong Kong. The intimation was filed by Company Secretary Rahul Sawale on August 4, 2026, in compliance with SEBI LODR Regulation 30.

powered bylight_fuzz_icon
47398129

*this image is generated using AI for illustrative purposes only.

Camlin Fine Sciences Limited has scheduled a Q1 FY27 earnings conference call on Tuesday, August 11, 2026 at 5:00 PM IST, to discuss the company's unaudited financial results for the quarter ended June 30, 2026. The intimation was filed pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company has clarified that discussions during the call will be based solely on publicly available information, and no unpublished price-sensitive information (UPSI) is intended to be discussed.

Call Details and Access Information

Investors and analysts are requested to pre-register for the call via the link provided by the company. The following dial-in access numbers have been made available for participation across multiple geographies:

Access Type: Details
Primary Number: +91 22 6280 1309 / +91 22 7115 8210
Toll Free – USA: 1 866 746 2133
Toll Free – UK: 0 808 101 1573
Toll Free – Singapore: 800 101 2045
Toll Free – Hong Kong: 800 964 448

Senior Management Participants

The earnings call will feature the following senior management representatives from Camlin Fine Sciences:

  • Mr. Ashish Dandekar – Chairman & Managing Director
  • Mr. Nirmal Momaya – Managing Director
  • Mr. Santosh Parab – Chief Financial Officer

RSVP and Investor Relations Contact

The call is being coordinated by Strategic Growth Advisors Pvt. Ltd. Interested participants may reach out to the investor relations team for further assistance:

Contact Person: Contact Number
Mr. Shrikant Sangani: +91 9619595686
Ms. Shaily Patwa: +91 9819494608

The company has noted that the scheduled date of the call is subject to change due to exigencies on the part of analysts, investors, or the company. The filing was signed by Rahul Sawale, Company Secretary & VP Legal, on August 4, 2026.

Historical Stock Returns for Camlin Fine Sciences

1 Day5 Days1 Month6 Months1 Year5 Years
+0.91%-2.31%-2.36%-25.01%-44.52%-26.31%

How might Camlin Fine Sciences' Q1 FY27 performance reflect the broader recovery trends in the global specialty chemicals sector?

What specific operational or strategic initiatives will management highlight to address potential margin pressures in the upcoming quarter?

Will the earnings call provide updated guidance on capital expenditure plans for capacity expansion in key product lines?

More News on Camlin Fine Sciences

1 Year Returns:-44.52%